- Growing backlog in equipment of EUR 321 million and services backlog of EUR 689 million, up 21%
Louvain-La-Neuve, Belgium, August 24, 2017 - IBA (Ion Beam Applications SA, EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its consolidated results for the first half of 2017.
Olivier Legrain, Chief Executive Officer of IBA SA commented: “Whilst the first half of 2017 has been challenging for IBA, we have worked tirelessly to rectify the issues with project management, including enhanced systems to manage the risk profile of projects, the creation of dedicated regional project management, improved internal processes and discussions with dedicated construction partners. We are encouraged by our strong pipeline and a backlog of equipment and services which now stands at over EUR 1 billion and are pleased with the strong growth from our Dosimetry business over the period.
The prospects for the proton therapy market remain strong, we have a burgeoning pipeline and the recent update of ASTRO and NCCN guidelines demonstrate the growing acceptance of proton therapy as a treatment modality for cancer. However, following on from a period of intense growth, the first half of 2017 has been slower, in line with the customary lumpiness which characterizes the proton therapy market. This combined with the increasing competition in the market is leading to limited visibility on the timing of new orders. However, IBA is optimally positioned to capitalize on the prospects on the proton therapy market and retains its focus on driving projects forward and leading the market with the most attractive proton therapy offering.”